Multiscale Peritumoral Ultrasound Machine Learning Scores and Pathological Response to Neoadjuvant Therapy in Breast Cancer.
Authors
Affiliations (2)
Affiliations (2)
- Department of Ultrasound, Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xi'an 710004, China.
- Department of Ultrasound, Ankang City Central Hospital, No. 85 Jinzhou South Road, Ankang 725000, China.
Abstract
<b>Background/Objectives:</b> Peritumoral ultrasound may capture tissue characteristics relevant to treatment sensitivity. In this study, we examined whether malignancy-related prediction scores (PS) were associated with pathological response to neoadjuvant therapy in breast cancer. <b>Methods:</b> Support vector machine classifiers were developed for 1, 3, 5, and 7 mm peritumoral regions using 1716 pathologically confirmed lesions. We assessed PS against postoperative Miller-Payne (MP) grade in 132 patients who completed neoadjuvant therapy and surgery. Ordinal logistic regression examined overall associations, interactions with hormone receptor (HR) status and Ki67, and treatment-stratified associations adjusted for both. Holm correction addressed multiple testing. The 7 mm classifier was refitted using 1584 patients outside the response cohort while retaining the originally selected features. <b>Results:</b> Higher 7 mm PS was associated with lower MP grade overall (odds ratio [OR] per 0.1-unit increase, 0.79; 95% confidence interval [CI], 0.66-0.95; Holm-adjusted <i>p</i> = 0.048). HR and Ki67 interactions remained significant at 1 mm (adjusted <i>p</i> = 0.049 and 0.036, respectively). In 60 complete cases receiving chemotherapy plus anti-HER2 therapy, the original 7 mm PS was associated with MP grade after adjustment (OR, 0.60; 95% CI, 0.42-0.85; adjusted <i>p</i> = 0.037). The refitted PS showed an attenuated association in these patients (OR, 0.709; 95% CI, 0.526-0.955; raw <i>p</i> = 0.0239; Holm-adjusted <i>p</i> = 0.0478). Associations in the original classifier test subsets (<i>n</i> = 22-26) were not significant after correction. <b>Conclusions:</b> The 7 mm score may complement HR and Ki67 for response assessment during chemotherapy plus anti-HER2 therapy. Interactions at 1 mm suggest variation with molecular characteristics. These findings warrant independent validation.